208:@0.017061:0.038809:0.056572:0.038809:0.056572:0.019212:0.017061:0.019212:0.013170:0.013170:0.013170
HANDBOOK OF ONCOLOGY:@0.084848:0.970015:0.320957:0.970015:0.320957:0.956010:0.084848:0.956010:0.011682:0.012657:0.012657:0.012726:0.009818:0.014864:0.014864:0.010109:0.004738:0.014864:0.008296:0.004738:0.014864:0.012657:0.013906:0.014864:0.007902:0.014864:0.014915:0.010126
Journal of Clinical Oncology. :@0.131885:0.078073:0.384927:0.078073:0.384927:0.064068:0.131885:0.064068:0.007902:0.010861:0.010057:0.004806:0.010092:0.011340:0.003079:0.010570:0.010861:0.005029:0.010570:0.013564:0.003079:0.003079:0.010092:0.003079:0.010724:0.011340:0.003079:0.010570:0.014522:0.010092:0.010724:0.010861:0.003079:0.010861:0.011169:0.008826:0.004396:0.004738
2018;41(4): :@0.390760:0.078073:0.480489:0.078073:0.480489:0.064068:0.390760:0.064068:0.009134:0.009134:0.009134:0.009134:0.004396:0.009134:0.009134:0.005969:0.009134:0.005969:0.004721:0.004738
379-384.:@0.131885:0.092243:0.196762:0.092243:0.196762:0.078238:0.131885:0.078238:0.009134:0.009134:0.009134:0.005337:0.009134:0.009134:0.009134:0.004738
98.:@0.084848:0.106413:0.108545:0.106413:0.108545:0.092408:0.084848:0.092408:0.009479:0.009479:0.004738
  Kitagawa R, Katsumata N, Shibata T, :@0.131885:0.106413:0.433846:0.106413:0.433846:0.092408:0.131885:0.092408:0.004738:-0.004738:0.009938:0.003250:0.005627:0.011511:0.011340:0.011511:0.014043:0.011511:0.005285:0.010211:0.004567:0.005285:0.009938:0.011511:0.005627:0.006465:0.010228:0.015873:0.011511:0.005627:0.011511:0.005285:0.012486:0.004567:0.005285:0.008347:0.010263:0.003250:0.011494:0.011511:0.005627:0.011511:0.005285:0.005371:0.004567:0.004738
et al:@0.434393:0.106413:0.471184:0.106413:0.471184:0.092408:0.434393:0.092408:0.010947:0.005627:0.005285:0.011511:0.003421
.:@0.471013:0.106413:0.475751:0.106413:0.475751:0.092408:0.471013:0.092408:0.004738
Paclitaxel plus carboplatin versus paclitax-:@0.131885:0.120583:0.475734:0.120583:0.475734:0.106578:0.131885:0.106578:0.009955:0.011511:0.010895:0.003250:0.003250:0.005627:0.011511:0.008039:0.010947:0.003250:0.004806:0.011494:0.003250:0.010228:0.006465:0.004806:0.010895:0.011511:0.004977:0.011494:0.011032:0.011494:0.003250:0.011511:0.005627:0.003250:0.010263:0.004806:0.009305:0.010947:0.004977:0.006465:0.010228:0.006465:0.004806:0.011494:0.011511:0.010895:0.003250:0.003250:0.005627:0.011511:0.008039:0.005679
el plus cisplatin in metastatic or recurrent :@0.131885:0.134753:0.480491:0.134753:0.480491:0.120748:0.131885:0.120748:0.010947:0.003250:0.006917:0.011494:0.003250:0.010228:0.006465:0.006917:0.010895:0.003250:0.006465:0.011494:0.003250:0.011511:0.005627:0.003250:0.010263:0.006917:0.003250:0.010263:0.006917:0.015873:0.010947:0.005627:0.011511:0.006465:0.005627:0.011511:0.005627:0.003250:0.010895:0.006917:0.011032:0.004977:0.006917:0.004907:0.010947:0.010895:0.010228:0.004977:0.004907:0.010947:0.010263:0.005797:0.004738
cervical  cancer:  the  open-label  rand-:@0.131885:0.148923:0.475765:0.148923:0.475765:0.134918:0.131885:0.134918:0.010895:0.010947:0.004977:0.009305:0.003250:0.010895:0.011511:0.003250:0.004738:0.008834:0.010895:0.011511:0.010263:0.010895:0.010947:0.004977:0.004567:0.004738:0.008833:0.005627:0.010263:0.010947:0.004738:0.008834:0.011032:0.011494:0.010947:0.010263:0.005508:0.003250:0.011511:0.011494:0.010947:0.003250:0.004738:0.008833:0.004977:0.011511:0.010263:0.011545:0.005679
omized phase III trial JCOG0505. :@0.131885:0.163093:0.396421:0.163093:0.396421:0.149087:0.131885:0.149087:0.011032:0.015873:0.003250:0.007098:0.010947:0.011545:0.004161:0.011494:0.010263:0.011511:0.006465:0.010947:0.004161:0.003695:0.003695:0.003695:0.004161:0.005627:0.004977:0.003250:0.011511:0.003250:0.004161:0.008073:0.013735:0.014693:0.014744:0.009305:0.009305:0.009305:0.009305:0.004563:0.846006
Journal of :@0.395874:0.163093:0.480506:0.163093:0.480506:0.149087:0.395874:0.149087:0.008073:0.011032:0.010228:0.004977:0.010263:0.011511:0.003250:0.004156:0.011032:0.005371:0.004738
Clinical Oncology. :@0.131885:0.177263:0.286663:0.177263:0.286663:0.163257:0.131885:0.163257:0.013735:0.003250:0.003250:0.010263:0.003250:0.010895:0.011511:0.003250:0.004567:0.014693:0.010263:0.010895:0.011032:0.003250:0.011032:0.011340:0.008997:0.004567:0.004738
2015;33(19):2129-2135.:@0.286492:0.177263:0.467028:0.177263:0.467028:0.163257:0.286492:0.163257:0.009305:0.009305:0.009305:0.009305:0.004567:0.009305:0.009305:0.006140:0.009305:0.009305:0.006140:0.004567:0.009305:0.009305:0.009305:0.009305:0.005508:0.009305:0.009305:0.009305:0.009305:0.004738
99.:@0.084848:0.191432:0.108538:0.191432:0.108538:0.177427:0.084848:0.177427:0.009476:0.009476:0.004738
  Hirte H, Kennedy EB, Elit L, :@0.131885:0.191432:0.353438:0.191432:0.353438:0.177427:0.131885:0.177427:0.004738:-0.004738:0.011682:0.003421:0.005148:0.005798:0.011118:0.006192:0.011682:0.004738:0.006192:0.010109:0.011118:0.010434:0.010434:0.011118:0.011716:0.009168:0.006192:0.009168:0.009818:0.004738:0.006192:0.009168:0.003421:0.003421:0.005798:0.006192:0.007902:0.004738:0.004738
et al:@0.354858:0.191432:0.393060:0.191432:0.393060:0.177427:0.354858:0.177427:0.011118:0.005798:0.006183:0.011682:0.003421
. Systemic:@0.393060:0.191432:0.475760:0.191432:0.475760:0.177427:0.393060:0.177427:0.004738:0.006192:0.008518:0.009168:0.006636:0.005798:0.011118:0.016044:0.003421:0.011067
therapy for recurrent, persistent, or meta-:@0.131885:0.205602:0.475770:0.205602:0.475770:0.191597:0.131885:0.191597:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.005600:0.005371:0.011203:0.005148:0.005595:0.005078:0.011118:0.011067:0.010399:0.005148:0.005077:0.011118:0.010434:0.005798:0.004738:0.005597:0.011665:0.011118:0.005148:0.006636:0.003421:0.006636:0.005798:0.011118:0.010434:0.005798:0.004738:0.005598:0.011203:0.005148:0.005600:0.016044:0.011118:0.005798:0.011682:0.005679
static cervical cancer: a clinical practice :@0.131885:0.219772:0.480501:0.219772:0.480501:0.205767:0.131885:0.205767:0.006636:0.005798:0.011682:0.005798:0.003421:0.011067:0.005448:0.011067:0.011118:0.005148:0.009476:0.003421:0.011067:0.011682:0.003421:0.005456:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.004729:0.005444:0.011682:0.005446:0.011067:0.003421:0.003421:0.010434:0.003421:0.011067:0.011682:0.003421:0.005456:0.011665:0.005148:0.011682:0.011067:0.005798:0.003421:0.011067:0.011118:0.004738
guideline. :@0.131885:0.233801:0.217920:0.233801:0.217920:0.219796:0.131885:0.219796:0.011511:0.010399:0.003421:0.011716:0.011118:0.003421:0.003421:0.010434:0.011118:0.004738:0.004738
Current  Oncology:@0.221375:0.233801:0.374374:0.233801:0.374374:0.219796:0.221375:0.219796:0.013906:0.010399:0.005148:0.005148:0.011118:0.010434:0.005798:0.004738:0.003438:0.014864:0.010434:0.011067:0.011203:0.003421:0.011203:0.011511:0.009168
. 2015;22(3): :@0.374374:0.233801:0.480489:0.233801:0.480489:0.219796:0.374374:0.219796:0.004738:0.008193:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.006312:0.009476:0.006312:0.004755:0.004738
211-219. :@0.131885:0.247830:0.203895:0.247830:0.203895:0.233825:0.131885:0.233825:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738:0.004738
100.    Frumovitz  M. Small- and large-cell  neu-:@0.084848:0.261859:0.475753:0.261859:0.475753:0.247853:0.084848:0.247853:0.009476:0.009476:0.009476:0.004738:0.004738:0.004738:0.004396:0.000000:0.008296:0.005148:0.010399:0.016044:0.011203:0.009476:0.003421:0.005798:0.007269:0.004738:0.003335:0.015719:0.004738:0.008090:0.008518:0.016044:0.011682:0.003421:0.003421:0.005679:0.008090:0.011682:0.010434:0.011716:0.008090:0.003421:0.011682:0.005167:0.011511:0.011118:0.005679:0.011067:0.011118:0.003421:0.003421:0.008090:0.008090:0.010434:0.011118:0.010399:0.623956
roendocrine. :@0.131885:0.275887:0.243301:0.275887:0.243301:0.261882:0.131885:0.261882:0.005078:0.011203:0.011118:0.010434:0.011716:0.011203:0.011067:0.005148:0.003421:0.010434:0.011118:0.004738:0.004738
Cervical Cancer. Oncology:@0.242636:0.275887:0.471029:0.275887:0.471029:0.261882:0.242636:0.261882:0.013906:0.011118:0.005148:0.009476:0.003421:0.011067:0.011682:0.003421:0.004105:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738:0.004086:0.014864:0.010434:0.011067:0.011203:0.003421:0.011203:0.011511:0.009168
. :@0.471029:0.275887:0.480505:0.275887:0.480505:0.261882:0.471029:0.261882:0.004738:0.004738
2016;30(1):70.:@0.131885:0.289916:0.244004:0.289916:0.244004:0.275911:0.131885:0.275911:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.006312:0.009476:0.006312:0.004738:0.009476:0.009476:0.004738
101.    Cihoric N, Tsikkinis A, Badra EV, :@0.084848:0.303945:0.386446:0.303945:0.386446:0.289940:0.084848:0.289940:0.009476:0.009476:0.009476:0.004738:0.004738:0.004738:0.004396:0.000000:0.013906:0.003421:0.010434:0.011203:0.005148:0.003421:0.011067:0.004841:0.012657:0.004738:0.004846:0.006890:0.006636:0.003421:0.008586:0.008586:0.003421:0.010434:0.003421:0.006636:0.004858:0.012657:0.004738:0.004846:0.009818:0.011682:0.011716:0.005148:0.011682:0.004858:0.009168:0.010201:0.004738:0.651106
et al:@0.386566:0.303945:0.423433:0.303945:0.423433:0.289940:0.386566:0.289940:0.011118:0.005798:0.004847:0.011682:0.003421
. High-:@0.423433:0.303945:0.475755:0.303945:0.475755:0.289940:0.423433:0.289940:0.004738:0.004858:0.011682:0.003421:0.011511:0.010434:0.005679
ly conformal combined radiotherapy with :@0.131885:0.317974:0.480518:0.317974:0.480518:0.303969:0.131885:0.303969:0.003421:0.009168:0.004139:0.011067:0.011203:0.010434:0.005371:0.011203:0.005614:0.016044:0.011682:0.003421:0.004139:0.011067:0.011203:0.016044:0.011665:0.003421:0.010434:0.011118:0.011716:0.004139:0.005148:0.011682:0.011716:0.003421:0.011203:0.005798:0.010434:0.011118:0.005148:0.011674:0.011665:0.009168:0.004139:0.014214:0.003421:0.005798:0.010434:0.004738
cisplatin and gemcitabine for  treatment :@0.131885:0.332003:0.480506:0.332003:0.480506:0.317997:0.131885:0.317997:0.011067:0.003421:0.006636:0.011665:0.003421:0.011682:0.005798:0.003421:0.010434:0.007663:0.011682:0.010434:0.011716:0.007663:0.011511:0.011118:0.016044:0.011067:0.003421:0.005798:0.011682:0.011665:0.003421:0.010434:0.011118:0.007663:0.005371:0.011203:0.005148:0.004738:0.002913:0.005798:0.005075:0.011118:0.011682:0.005798:0.016044:0.011118:0.010434:0.005798:0.004738
of  loco-regionally advanced cervical :@0.131885:0.346031:0.480500:0.346031:0.480500:0.332026:0.131885:0.332026:0.011203:0.005371:0.004738:0.011581:0.003421:0.011203:0.011067:0.011203:0.005679:0.005071:0.011118:0.011511:0.003421:0.011203:0.010434:0.011682:0.003421:0.003421:0.009168:0.016335:0.011682:0.011716:0.009476:0.011682:0.010434:0.011067:0.011118:0.011716:0.016335:0.011067:0.011118:0.005148:0.009476:0.003421:0.011067:0.011682:0.003421:0.004738
cancer – a retrospective study. :@0.131885:0.360060:0.395472:0.360060:0.395472:0.346055:0.131885:0.346055:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.005268:0.008552:0.005268:0.011682:0.005268:0.005078:0.011118:0.005798:0.005073:0.011203:0.006636:0.011665:0.011118:0.011067:0.005798:0.003421:0.009476:0.011118:0.005268:0.006636:0.005798:0.010399:0.011716:0.009168:0.004738:0.004738
Radiation :@0.396002:0.360060:0.480481:0.360060:0.480481:0.346055:0.396002:0.346055:0.010382:0.011682:0.011716:0.003421:0.011682:0.005798:0.003421:0.011203:0.010434:0.004738
Oncology:@0.131885:0.374089:0.214756:0.374089:0.214756:0.360084:0.131885:0.360084:0.014864:0.010434:0.011067:0.011203:0.003421:0.011203:0.011511:0.009168
. 2017;12(1):202.:@0.214756:0.374089:0.345827:0.374089:0.345827:0.360084:0.214756:0.360084:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.006312:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.004738
102.    Rosen VM, Guerra I, McCormack M, :@0.084848:0.388118:0.434455:0.388118:0.434455:0.374113:0.084848:0.374113:0.009476:0.009476:0.009476:0.004738:0.004738:0.004738:0.004396:0.000000:0.010382:0.011203:0.006636:0.011118:0.010434:0.004635:0.012007:0.015719:0.004738:0.004652:0.014915:0.010399:0.011118:0.005148:0.005148:0.011682:0.004640:0.003866:0.004738:0.004652:0.015719:0.011067:0.013906:0.011203:0.005615:0.016044:0.011682:0.011067:0.008586:0.004652:0.015719:0.004738:0.480664
et al.:@0.434369:0.388118:0.475770:0.388118:0.475770:0.374113:0.434369:0.374113:0.011118:0.005798:0.004644:0.011682:0.003421:0.004738
 :@0.475770:0.388118:0.480508:0.388118:0.480508:0.374113:0.475770:0.374113:0.004738
Systematic review and network meta-:@0.131885:0.402147:0.475736:0.402147:0.475736:0.388141:0.131885:0.388141:0.008518:0.009168:0.006636:0.005798:0.011118:0.016044:0.011682:0.005798:0.003421:0.011067:0.012384:0.005078:0.011118:0.009476:0.003421:0.011118:0.014214:0.012384:0.011682:0.010434:0.011716:0.012384:0.010434:0.011118:0.005798:0.014214:0.011203:0.005148:0.008573:0.012384:0.016044:0.011118:0.005798:0.011682:0.005679
analysis of bevacizumab plus first-line to-:@0.131885:0.416175:0.475763:0.416175:0.475763:0.402170:0.131885:0.402170:0.011682:0.010434:0.011682:0.003421:0.009168:0.006636:0.003421:0.006636:0.006801:0.011203:0.005371:0.006780:0.011665:0.011118:0.009476:0.011682:0.011067:0.003421:0.007269:0.010399:0.016044:0.011682:0.011665:0.006792:0.011665:0.003421:0.010399:0.006636:0.006792:0.004165:0.004165:0.005148:0.006636:0.005798:0.005679:0.003421:0.003421:0.010434:0.011118:0.006782:0.005798:0.011203:0.005679
potecan-paclitaxel or cisplatin-paclitaxel :@0.131885:0.430204:0.480486:0.430204:0.480486:0.416199:0.131885:0.416199:0.011665:0.011203:0.005798:0.011118:0.011067:0.011682:0.010434:0.005679:0.011665:0.011682:0.011067:0.003421:0.003421:0.005798:0.011682:0.008210:0.011118:0.003421:0.006329:0.011203:0.005148:0.006329:0.011067:0.003421:0.006636:0.011665:0.003421:0.011682:0.005798:0.003421:0.010434:0.005679:0.011679:0.011682:0.011067:0.003421:0.003421:0.005798:0.011682:0.008210:0.011118:0.003421:0.004738
versus non-bevacizumab-containing ther-:@0.131885:0.444233:0.475751:0.444233:0.475751:0.430228:0.131885:0.430228:0.009476:0.011118:0.005148:0.006636:0.010399:0.006636:0.003985:0.010434:0.011203:0.010434:0.005679:0.011665:0.011118:0.009476:0.011682:0.011067:0.003421:0.007269:0.010399:0.016044:0.011682:0.011665:0.005679:0.011067:0.011203:0.010434:0.005798:0.011682:0.003421:0.010434:0.003421:0.010434:0.011511:0.003985:0.005798:0.010434:0.011118:0.005131:0.005679
apies in persistent, recurrent, or metastat-:@0.131885:0.458262:0.475768:0.458262:0.475768:0.444257:0.131885:0.444257:0.011682:0.011665:0.003421:0.011118:0.006636:0.005297:0.003421:0.010434:0.005285:0.011665:0.011118:0.005148:0.006636:0.003421:0.006636:0.005798:0.011118:0.010434:0.005798:0.004738:0.005285:0.005077:0.011118:0.011067:0.010399:0.005148:0.005071:0.011118:0.010434:0.005798:0.004738:0.005285:0.011203:0.005148:0.005285:0.016044:0.011118:0.005798:0.011682:0.006636:0.005798:0.011682:0.005798:0.005679
ic cervical cancer. :@0.131885:0.472291:0.298540:0.472291:0.298540:0.458285:0.131885:0.458285:0.003421:0.011067:0.008518:0.011067:0.011118:0.005148:0.009476:0.003421:0.011067:0.011682:0.003421:0.008518:0.011067:0.011682:0.010434:0.011067:0.011118:0.003890:0.004738:0.004738
International  Journal :@0.302296:0.472291:0.480505:0.472291:0.480505:0.458285:0.302296:0.458285:0.003866:0.010434:0.005798:0.011118:0.005148:0.010434:0.011682:0.005798:0.003421:0.011203:0.010434:0.011682:0.003412:0.004738:0.003770:0.008244:0.011203:0.010399:0.005148:0.010434:0.011682:0.003421:0.004738
of  Gynecological Cancer.:@0.131885:0.486319:0.371608:0.486319:0.371608:0.472314:0.131885:0.472314:0.011203:0.005371:0.004738:0.010969:0.014915:0.009168:0.010434:0.011118:0.011067:0.011203:0.003421:0.011203:0.011511:0.003421:0.011067:0.011682:0.003421:0.015719:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738
 2017;27(6): :@0.371586:0.486319:0.480489:0.486319:0.480489:0.472314:0.371586:0.472314:0.015719:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.006312:0.009476:0.006312:0.004755:0.004738
1237-1246.:@0.131885:0.500348:0.218108:0.500348:0.218108:0.486343:0.131885:0.486343:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.009476:0.004738
103.    Lin K-T, Wang L-H. New dimension of glu-:@0.084848:0.514377:0.475762:0.514377:0.475762:0.500372:0.084848:0.500372:0.009476:0.009476:0.009476:0.004738:0.004738:0.004738:0.004396:0.000000:0.007902:0.003421:0.010434:0.006705:0.010109:0.005679:0.005535:0.004738:0.006693:0.015568:0.011682:0.010434:0.011511:0.006695:0.007902:0.005679:0.011682:0.004738:0.006695:0.012657:0.011118:0.014214:0.006691:0.011716:0.003421:0.016044:0.011118:0.010434:0.006636:0.003421:0.011203:0.010434:0.006691:0.011203:0.005371:0.006693:0.011511:0.003421:0.010399:0.256648
cocorticoids  in cancer  treatment. :@0.131885:0.528406:0.437438:0.528406:0.437438:0.514401:0.131885:0.514401:0.011067:0.011203:0.011067:0.011203:0.005148:0.005798:0.003421:0.011067:0.011203:0.003421:0.011716:0.006636:0.004738:0.007220:0.003421:0.010434:0.011973:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738:0.007220:0.005798:0.005077:0.011118:0.011682:0.005798:0.016044:0.011118:0.010434:0.005798:0.004738:0.004738
Ste-:@0.444639:0.528406:0.475751:0.528406:0.475751:0.514401:0.444639:0.514401:0.008518:0.005798:0.011118:0.005679
roids.:@0.131885:0.542435:0.174749:0.542435:0.174749:0.528429:0.131885:0.528429:0.005148:0.011203:0.003421:0.011716:0.006636:0.004738
 2016;111:84-88.:@0.174749:0.542435:0.303613:0.542435:0.303613:0.528429:0.174749:0.528429:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.005679:0.009476:0.009476:0.004738
104.    McKay LI, Cidlowski JA. Corticosteroids in :@0.084848:0.556463:0.480493:0.556463:0.480493:0.542458:0.084848:0.542458:0.009476:0.009476:0.009476:0.004738:0.004738:0.004738:0.004396:0.000000:0.015719:0.011067:0.010109:0.011682:0.009168:0.006055:0.007902:0.003866:0.004738:0.006055:0.013906:0.003421:0.011716:0.003421:0.011203:0.014214:0.006636:0.008586:0.003421:0.006055:0.008244:0.012657:0.004738:0.006038:0.013906:0.011203:0.005140:0.005798:0.003421:0.011067:0.011203:0.006636:0.005798:0.011118:0.005075:0.011203:0.003421:0.011716:0.006636:0.006055:0.003421:0.010434:0.189760
the Treatment of Neoplasms. In: Kufe DW, :@0.131885:0.570492:0.480517:0.570492:0.480517:0.556487:0.131885:0.556487:0.005798:0.010434:0.011118:0.005371:0.006775:0.005077:0.011118:0.011682:0.005798:0.016044:0.011118:0.010434:0.005798:0.005362:0.011203:0.005371:0.005371:0.012657:0.011118:0.011203:0.011665:0.003421:0.011682:0.006636:0.016044:0.006636:0.004738:0.005371:0.003866:0.010434:0.004738:0.005371:0.010109:0.010399:0.005371:0.011118:0.005371:0.012726:0.014611:0.004738:0.004738
Pollock RE, Weichselbaum RR, :@0.131885:0.584521:0.389934:0.584521:0.389934:0.570516:0.131885:0.570516:0.010126:0.011203:0.003421:0.003421:0.011203:0.011067:0.008586:0.007286:0.010382:0.009168:0.004738:0.007286:0.015618:0.011118:0.003421:0.011067:0.010434:0.006636:0.011118:0.003421:0.011665:0.011682:0.010399:0.016044:0.007297:0.010382:0.010382:0.004738:0.004738
et al:@0.392482:0.584521:0.431788:0.584521:0.431788:0.570516:0.392482:0.570516:0.011118:0.005798:0.007286:0.011682:0.003421
, edi-:@0.431788:0.584521:0.475746:0.584521:0.475746:0.570516:0.431788:0.570516:0.004738:0.007286:0.011118:0.011716:0.003421:0.005679
tors. :@0.131885:0.598550:0.170148:0.598550:0.170148:0.584545:0.131885:0.584545:0.005798:0.011203:0.005148:0.006636:0.004738:0.004738
Holland-Frei Cancer Medicine.:@0.175741:0.598550:0.439730:0.598550:0.439730:0.584545:0.175741:0.584545:0.011682:0.011203:0.003421:0.003421:0.011682:0.010434:0.011716:0.005679:0.008296:0.005148:0.011118:0.003421:0.010331:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.010331:0.015719:0.011118:0.011716:0.003421:0.011067:0.003421:0.010434:0.011118:0.004738
 6th :@0.439730:0.598550:0.480506:0.598550:0.480506:0.584545:0.439730:0.584545:0.010331:0.009476:0.005798:0.010434:0.004738
edition.  Hamilton  (ON): BC Decker; :@0.131885:0.612579:0.480505:0.612579:0.480505:0.598573:0.131885:0.598573:0.011118:0.011716:0.003421:0.005798:0.003421:0.011203:0.010434:0.004738:0.004738:0.014067:0.011682:0.011682:0.016044:0.003421:0.003421:0.005798:0.011203:0.010434:0.004738:0.014068:0.006312:0.014864:0.012657:0.006312:0.004738:0.018815:0.009818:0.013906:0.018815:0.012726:0.011118:0.011067:0.008586:0.011118:0.005148:0.004738:0.004738
2003.  Available  from:  https://www.ncbi.:@0.131885:0.626607:0.475755:0.626607:0.475755:0.612602:0.131885:0.612602:0.009476:0.009476:0.009476:0.009476:0.004738:0.004738:0.006192:0.011400:0.009476:0.011682:0.003421:0.003421:0.011682:0.011665:0.003421:0.011118:0.004738:0.006202:0.005371:0.005078:0.011203:0.016044:0.004738:0.004738:0.006178:0.010434:0.005798:0.005798:0.011665:0.006636:0.004738:0.007475:0.007475:0.014214:0.014214:0.014214:0.004738:0.010434:0.011067:0.011665:0.003421:0.092470
nlm.nih.gov/books/NBK13383/:@0.131885:0.640636:0.379420:0.640636:0.379420:0.626631:0.131885:0.626631:0.010434:0.003421:0.016044:0.004738:0.010434:0.003421:0.010434:0.004738:0.011511:0.011203:0.009476:0.007475:0.011665:0.011203:0.011203:0.008586:0.006636:0.007475:0.012657:0.009818:0.010109:0.009476:0.009476:0.009476:0.009476:0.009476:0.007475
105.    Ryan CJ, Smith MR, Fizazi K, :@0.084848:0.654665:0.361101:0.654665:0.361101:0.640660:0.084848:0.640660:0.009479:0.009479:0.009479:0.004736:0.004729:0.004738:0.004396:0.000000:0.010588:0.008826:0.011340:0.010092:0.006397:0.013564:0.007902:0.004396:0.006397:0.008176:0.015702:0.003079:0.005456:0.010092:0.006397:0.015377:0.010040:0.004396:0.006397:0.007954:0.003079:0.006927:0.011340:0.006927:0.003079:0.006397:0.009767:0.004396:0.004738
et al:@0.362760:0.654665:0.400150:0.654665:0.400150:0.640660:0.362760:0.640660:0.010776:0.005456:0.006397:0.011340:0.003421
 Abirater-:@0.399808:0.654665:0.475786:0.654665:0.475786:0.640660:0.399808:0.640660:0.006397:0.012315:0.011323:0.003079:0.004806:0.011340:0.005456:0.010776:0.004806:0.005679
one acetate plus prednisone versus place-:@0.131885:0.668694:0.475750:0.668694:0.475750:0.654688:0.131885:0.654688:0.010861:0.010092:0.010776:0.005166:0.011340:0.010724:0.010776:0.005456:0.011340:0.005456:0.010776:0.005166:0.011323:0.003079:0.010057:0.006294:0.005166:0.011323:0.004736:0.010776:0.011374:0.010092:0.003079:0.006294:0.010861:0.010092:0.010776:0.005166:0.009134:0.010776:0.004806:0.006294:0.010057:0.006294:0.005166:0.011323:0.003079:0.011340:0.010724:0.010776:0.005679
bo plus prednisone in chemotherapy-naive :@0.131885:0.682723:0.480520:0.682723:0.480520:0.668717:0.131885:0.668717:0.011323:0.010861:0.004379:0.011323:0.003079:0.010057:0.006294:0.004379:0.011323:0.004736:0.010776:0.011374:0.010092:0.003079:0.006294:0.010861:0.010092:0.010776:0.004379:0.003079:0.010092:0.004379:0.010724:0.010092:0.010776:0.015702:0.010861:0.005456:0.010092:0.010776:0.004806:0.011340:0.011323:0.008826:0.005337:0.010092:0.011340:0.003079:0.009134:0.011116:0.004738
men with metastatic castration-resistant :@0.131885:0.696751:0.480503:0.696751:0.480503:0.682746:0.131885:0.682746:0.015702:0.010776:0.010092:0.013512:0.013872:0.003079:0.005456:0.010092:0.013512:0.015702:0.010776:0.005456:0.011340:0.006294:0.005456:0.011340:0.005456:0.003079:0.010724:0.013512:0.010724:0.011340:0.006294:0.005456:0.004806:0.011340:0.005456:0.003079:0.010861:0.010092:0.005337:0.004736:0.010776:0.006294:0.003079:0.006294:0.005456:0.011340:0.010092:0.005797:0.004738
prostate cancer (COU-AA-302): final overall :@0.131885:0.710780:0.480503:0.710780:0.480503:0.696775:0.131885:0.696775:0.011323:0.004736:0.010861:0.006294:0.005456:0.011340:0.005456:0.010776:0.003818:0.010724:0.011340:0.010092:0.010724:0.010776:0.004806:0.003818:0.005969:0.013564:0.014522:0.010861:0.005337:0.012315:0.012315:0.005337:0.009134:0.009134:0.009134:0.005969:0.004396:0.003816:0.003994:0.003994:0.010092:0.011340:0.003079:0.003818:0.010861:0.009134:0.010776:0.004806:0.011340:0.003079:0.003424:0.004738
survival analysis of a randomised, double-:@0.131885:0.724809:0.475717:0.724809:0.475717:0.710804:0.131885:0.710804:0.006294:0.010057:0.004806:0.009134:0.003079:0.009134:0.011340:0.003079:0.007218:0.011340:0.010092:0.011340:0.003079:0.008826:0.006294:0.003079:0.006294:0.007218:0.010861:0.005029:0.007218:0.011340:0.007218:0.004806:0.011340:0.010092:0.011374:0.010861:0.015702:0.003079:0.006294:0.010776:0.011374:0.004396:0.007218:0.011374:0.010861:0.010057:0.011323:0.003079:0.010776:0.005679
blind, placebo-controlled phase 3 study. :@0.131885:0.738838:0.480469:0.738838:0.480469:0.724832:0.131885:0.724832:0.011323:0.003079:0.003079:0.010092:0.011374:0.004396:0.009749:0.011323:0.003079:0.011340:0.010724:0.010776:0.011323:0.010861:0.005337:0.010724:0.010861:0.010092:0.005456:0.004736:0.010861:0.003079:0.003079:0.010776:0.011374:0.009749:0.011323:0.010092:0.011340:0.006294:0.010776:0.009749:0.009134:0.009749:0.006294:0.005456:0.010057:0.011374:0.008826:0.004736:0.004738
The Lancet Oncology:@0.131885:0.752867:0.304913:0.752867:0.304913:0.738861:0.131885:0.738861:0.006944:0.010092:0.010776:0.004396:0.007560:0.011340:0.010092:0.010724:0.010776:0.005456:0.004396:0.014522:0.010092:0.010724:0.010861:0.003079:0.010861:0.011169:0.009168
. 2015;16(2):152-60.:@0.304571:0.752867:0.453772:0.752867:0.453772:0.738861:0.304571:0.738861:0.004396:0.004396:0.009134:0.009134:0.009134:0.009134:0.004396:0.009134:0.009134:0.005969:0.009134:0.005969:0.004396:0.009134:0.009134:0.009134:0.005337:0.009134:0.009134:0.004738
106.    Nussbaum N, George DJ, Abernethy AP, :@0.084848:0.766895:0.480498:0.766895:0.480498:0.752890:0.084848:0.752890:0.009476:0.009476:0.009476:0.004738:0.004738:0.004738:0.004396:0.000000:0.012657:0.010399:0.006636:0.006636:0.011665:0.011682:0.010399:0.016044:0.007269:0.012657:0.004738:0.007269:0.014915:0.011118:0.011203:0.005148:0.011511:0.011118:0.007269:0.012726:0.008244:0.004738:0.007269:0.012657:0.011665:0.011118:0.005490:0.010434:0.011118:0.005798:0.010434:0.009168:0.007269:0.012657:0.008013:0.004738:-0.116328
et al:@0.131885:0.780924:0.168950:0.780924:0.168950:0.766919:0.131885:0.766919:0.011118:0.005798:0.005046:0.011682:0.003421
. Patient experience in the treatment :@0.168950:0.780924:0.480518:0.780924:0.480518:0.766919:0.168950:0.766919:0.004738:0.005046:0.010126:0.011682:0.005798:0.003421:0.011118:0.010434:0.005798:0.005046:0.011118:0.008210:0.011665:0.011118:0.005148:0.003421:0.011118:0.010434:0.011067:0.011118:0.005046:0.003421:0.010434:0.005046:0.005798:0.010434:0.011118:0.005046:0.005798:0.005075:0.011118:0.011682:0.005798:0.016044:0.011118:0.010434:0.005798:0.004738
of metastatic castration-resistant prostate :@0.131885:0.794953:0.480500:0.794953:0.480500:0.780948:0.131885:0.780948:0.011203:0.005371:0.004705:0.016044:0.011118:0.005798:0.011682:0.006636:0.005798:0.011682:0.005798:0.003421:0.011067:0.004711:0.011067:0.011682:0.006636:0.005798:0.005148:0.011682:0.005798:0.003421:0.011203:0.010434:0.005679:0.005073:0.011118:0.006636:0.003421:0.006636:0.005798:0.011682:0.010434:0.005798:0.004712:0.011665:0.005080:0.011203:0.006636:0.005798:0.011682:0.005798:0.011118:0.004738
cancer:  state  of  the  science.  Prostate :@0.131885:0.808982:0.480503:0.808982:0.480503:0.794976:0.131885:0.794976:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738:0.004738:0.006583:0.006636:0.005798:0.011682:0.005798:0.011118:0.004738:0.006592:0.011203:0.005371:0.004738:0.006592:0.005798:0.010434:0.011118:0.004738:0.006587:0.006636:0.011067:0.003421:0.011118:0.010434:0.011067:0.011118:0.004738:0.004738:0.006590:0.010126:0.005075:0.011203:0.006636:0.005798:0.011682:0.005798:0.011118:0.004738
cancer and prostatic diseases. 2016;9(2): :@0.131885:0.823011:0.480482:0.823011:0.480482:0.809005:0.131885:0.809005:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.006123:0.011682:0.010434:0.011716:0.006123:0.011665:0.005080:0.011203:0.006636:0.005798:0.011682:0.005798:0.003421:0.011067:0.006123:0.011716:0.003421:0.006636:0.011118:0.011682:0.006636:0.011118:0.006636:0.004738:0.006134:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.006312:0.009476:0.006312:0.004738:0.004738
111-121.:@0.131885:0.837039:0.199157:0.837039:0.199157:0.823034:0.131885:0.823034:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
107.    Hughes T, Klairmont M, Broucek J, :@0.084848:0.851068:0.427589:0.851068:0.427589:0.837063:0.084848:0.837063:0.009476:0.009476:0.009476:0.004738:0.004738:0.004738:0.004396:0.000000:0.011682:0.010399:0.011511:0.010434:0.011118:0.006636:0.008090:0.005542:0.004738:0.008090:0.010109:0.003421:0.011682:0.003421:0.005629:0.016044:0.011203:0.010434:0.005798:0.008090:0.015719:0.004738:0.008090:0.009818:0.005082:0.011203:0.010399:0.011067:0.011118:0.008586:0.008090:0.008244:0.004738:-0.185852
et al:@0.430941:0.851068:0.471051:0.851068:0.471051:0.837063:0.430941:0.837063:0.011118:0.005798:0.008090:0.011682:0.003421
. :@0.471051:0.851068:0.480527:0.851068:0.480527:0.837063:0.471051:0.837063:0.004738:0.004738
The prognostic significance of stable dis-:@0.131885:0.865238:0.475758:0.865238:0.475758:0.851233:0.131885:0.851233:0.007286:0.010434:0.011118:0.006703:0.011665:0.005080:0.011203:0.011511:0.010434:0.011203:0.006636:0.005798:0.003421:0.011067:0.006710:0.006636:0.003421:0.011511:0.010434:0.003421:0.004165:0.004165:0.011067:0.011682:0.010434:0.011067:0.011118:0.006707:0.011203:0.005371:0.006707:0.006636:0.005798:0.011682:0.011665:0.003421:0.011118:0.006722:0.011716:0.003421:0.006636:0.005679
ease following high-dose interleukin-2 (IL-:@0.131885:0.879408:0.475768:0.879408:0.475768:0.865403:0.131885:0.865403:0.011118:0.011682:0.006636:0.011118:0.006192:0.005371:0.011203:0.003421:0.003421:0.011203:0.014214:0.003421:0.010434:0.011511:0.006192:0.010434:0.003421:0.011511:0.010434:0.005679:0.011716:0.011203:0.006636:0.011118:0.006192:0.003421:0.010434:0.005798:0.011118:0.005148:0.003421:0.011118:0.010399:0.008586:0.003421:0.010434:0.005679:0.009476:0.006192:0.006312:0.003866:0.007902:0.005679
2) treatment  in patients with metastatic:@0.131885:0.893578:0.475755:0.893578:0.475755:0.879573:0.131885:0.879573:0.009476:0.006312:0.008381:0.005798:0.005077:0.011118:0.011682:0.005798:0.016044:0.011118:0.010434:0.005798:0.004738:0.003633:0.003421:0.010434:0.008381:0.011665:0.011682:0.005798:0.003421:0.011118:0.010434:0.005798:0.006636:0.008381:0.014214:0.003421:0.005798:0.010434:0.008381:0.016044:0.011118:0.005798:0.011682:0.006636:0.005798:0.011682:0.005798:0.003421:0.011067
melanoma  and renal cell carcinoma. :@0.131885:0.907748:0.480513:0.907748:0.480513:0.893742:0.131885:0.893742:0.016044:0.011118:0.003421:0.011682:0.010434:0.011203:0.016044:0.011682:0.004738:0.008082:0.011682:0.010434:0.011716:0.012828:0.005078:0.011118:0.010434:0.011682:0.003421:0.012828:0.011067:0.011118:0.003421:0.003421:0.012828:0.011067:0.011682:0.005029:0.011067:0.003421:0.010434:0.011203:0.016044:0.011682:0.004738:0.004738
Cancer  Immunology,  Immunotherapy:@0.131885:0.921918:0.471034:0.921918:0.471034:0.907912:0.131885:0.907912:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738:0.012642:0.003866:0.016044:0.016044:0.010399:0.010434:0.011203:0.003421:0.011203:0.011511:0.009168:0.004738:0.004738:0.012642:0.003866:0.016044:0.016044:0.010399:0.010434:0.011203:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168
. :@0.471034:0.921918:0.480510:0.921918:0.480510:0.907912:0.471034:0.907912:0.004738:0.004738
2015;64(4):459-465.:@0.131885:0.936088:0.287586:0.936088:0.287586:0.922082:0.131885:0.922082:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.006312:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
108.    Cervia D, Assi E, De Palma C, :@0.524242:0.078238:0.805848:0.078238:0.805848:0.064233:0.524242:0.064233:0.009479:0.009479:0.009479:0.004736:0.004387:0.004738:0.004738:0.000000:0.013564:0.010776:0.004806:0.009134:0.003079:0.011340:0.004464:0.012384:0.004396:0.004464:0.012315:0.006294:0.006294:0.003079:0.004464:0.008826:0.004396:0.004464:0.012384:0.010776:0.004464:0.009784:0.011340:0.003079:0.015702:0.011340:0.004464:0.013564:0.004396:0.560004
et al:@0.805575:0.078238:0.841032:0.078238:0.841032:0.064233:0.805575:0.064233:0.010776:0.005456:0.004464:0.011340:0.003421
. Essential :@0.840690:0.078238:0.919871:0.078238:0.919871:0.064233:0.840690:0.064233:0.004396:0.004464:0.008826:0.006294:0.006294:0.010776:0.010092:0.005456:0.003079:0.011340:0.003426:0.004738
role for acid sphingomyelinase-inhibited :@0.571279:0.092525:0.919866:0.092525:0.919866:0.078520:0.571279:0.078520:0.004736:0.010861:0.003079:0.010776:0.013427:0.005029:0.010861:0.004806:0.013427:0.011340:0.010724:0.003079:0.011374:0.013427:0.006294:0.011323:0.010092:0.003079:0.010092:0.011169:0.010861:0.015702:0.008826:0.010776:0.003079:0.003079:0.010092:0.011340:0.006294:0.010776:0.005337:0.003079:0.010092:0.010092:0.003079:0.011323:0.003079:0.005456:0.010776:0.011718:0.004738
autophagy in melanoma response to cispl-:@0.571279:0.106813:0.915144:0.106813:0.915144:0.092808:0.571279:0.092808:0.011340:0.010057:0.005456:0.010861:0.011323:0.010092:0.011340:0.011169:0.008826:0.004738:0.003079:0.010092:0.004738:0.015702:0.010776:0.003079:0.011340:0.010092:0.010861:0.015702:0.011340:0.004738:0.004736:0.010776:0.006294:0.011323:0.010861:0.010092:0.006294:0.010776:0.004738:0.005456:0.010861:0.004738:0.010724:0.003079:0.006294:0.011323:0.003079:0.005679
atin. :@0.571279:0.121100:0.610380:0.121100:0.610380:0.107095:0.571279:0.107095:0.011340:0.005456:0.003079:0.010092:0.004396:0.004738
Oncotarget.:@0.610038:0.121100:0.709978:0.121100:0.709978:0.107095:0.610038:0.107095:0.014522:0.010092:0.010724:0.010861:0.005456:0.011340:0.004806:0.011169:0.010776:0.005456:0.004738
 2016;7(18):24995-25009.:@0.709636:0.121100:0.900111:0.121100:0.900111:0.107095:0.709636:0.107095:0.004396:0.009134:0.009134:0.009134:0.009134:0.004396:0.009134:0.005969:0.009134:0.009134:0.005969:0.004396:0.009134:0.009134:0.009134:0.009134:0.009134:0.005337:0.009134:0.009134:0.009134:0.009134:0.009134:0.004738
109.    Karagöz B, Bilgi O, Özgün A, :@0.524242:0.135388:0.819019:0.135388:0.819019:0.121383:0.524242:0.121383:0.009479:0.009479:0.009479:0.004734:0.004731:0.004738:0.004396:0.000000:0.009938:0.011511:0.004977:0.011511:0.011340:0.011032:0.007098:0.008142:0.009647:0.004567:0.008142:0.009647:0.003250:0.003250:0.011340:0.003250:0.008142:0.014693:0.004567:0.008142:0.014693:0.007098:0.011340:0.010228:0.010263:0.008142:0.012486:0.004567:0.463707
et al:@0.822423:0.135388:0.862070:0.135388:0.862070:0.121383:0.822423:0.121383:0.010947:0.005627:0.008142:0.011511:0.003421
. Long :@0.861899:0.135388:0.919880:0.135388:0.919880:0.121383:0.861899:0.121383:0.004567:0.008142:0.007731:0.011032:0.010263:0.011508:0.004738
term survival with the combination of inter-:@0.571279:0.149675:0.915161:0.149675:0.915161:0.135670:0.571279:0.135670:0.005627:0.010947:0.005449:0.015873:0.004367:0.006465:0.010228:0.004977:0.009305:0.003250:0.009305:0.011511:0.003250:0.004368:0.014043:0.003250:0.005627:0.010263:0.004368:0.005627:0.010263:0.010947:0.004368:0.010895:0.011032:0.015873:0.011494:0.003250:0.010263:0.011511:0.005627:0.003250:0.011032:0.010263:0.004368:0.011032:0.005200:0.004368:0.003250:0.010263:0.005627:0.010947:0.004977:0.005679
feron and chemotherapy in metastatic :@0.571279:0.163963:0.919929:0.163963:0.919929:0.149958:0.571279:0.149958:0.005200:0.010947:0.004906:0.011032:0.010263:0.011101:0.011511:0.010263:0.011545:0.011101:0.010895:0.010263:0.010947:0.015873:0.011032:0.005627:0.010263:0.010947:0.004977:0.011511:0.011494:0.008997:0.011101:0.003250:0.010263:0.011101:0.015873:0.010947:0.005627:0.011511:0.006465:0.005627:0.011511:0.005627:0.003250:0.011065:0.004738
melanoma. :@0.571279:0.178250:0.670844:0.178250:0.670844:0.164245:0.571279:0.164245:0.015873:0.010947:0.003250:0.011511:0.010263:0.011032:0.015873:0.011511:0.004567:0.004738
Journal of the Egyptian Na-:@0.675205:0.178250:0.915162:0.178250:0.915162:0.164245:0.675205:0.164245:0.008073:0.011032:0.010228:0.004977:0.010263:0.011511:0.003250:0.009100:0.011032:0.005200:0.009100:0.005627:0.010263:0.010947:0.009100:0.008997:0.011340:0.008997:0.011494:0.005627:0.003250:0.011511:0.010263:0.009100:0.012486:0.011511:0.005679
tional Cancer Institute:@0.571279:0.192538:0.749575:0.192538:0.749575:0.178533:0.571279:0.178533:0.005627:0.003250:0.011032:0.010263:0.011511:0.003250:0.004567:0.013735:0.011511:0.010263:0.010895:0.010947:0.004977:0.004567:0.003695:0.010263:0.006465:0.005627:0.003250:0.005627:0.010228:0.005627:0.011118
. 2015;27(3):161-163.:@0.749404:0.192538:0.911160:0.192538:0.911160:0.178533:0.749404:0.178533:0.004567:0.004567:0.009305:0.009305:0.009305:0.009305:0.004567:0.009305:0.009305:0.006140:0.009305:0.006140:0.004567:0.009305:0.009305:0.009305:0.005508:0.009305:0.009305:0.009305:0.004738
110.    Wilson MA, Zhao F, Khare S, :@0.524242:0.206825:0.813826:0.206825:0.813826:0.192820:0.524242:0.192820:0.009476:0.009476:0.009476:0.004738:0.004738:0.004738:0.004396:0.000000:0.016523:0.003421:0.003421:0.006636:0.011203:0.010434:0.007782:0.015719:0.012657:0.004738:0.007782:0.008210:0.010434:0.011682:0.011203:0.007782:0.006205:0.004738:0.007782:0.010109:0.010434:0.011682:0.005073:0.011118:0.007782:0.008518:0.004738:0.364991
et al:@0.816870:0.206825:0.856672:0.206825:0.856672:0.192820:0.816870:0.192820:0.011118:0.005798:0.007782:0.011682:0.003421
. Copy :@0.856672:0.206825:0.919873:0.206825:0.919873:0.192820:0.856672:0.192820:0.004738:0.007782:0.013906:0.011203:0.011665:0.009168:0.004738
number changes are associated with re-:@0.571279:0.221113:0.915161:0.221113:0.915161:0.207108:0.571279:0.207108:0.010434:0.010399:0.016044:0.011665:0.011118:0.005148:0.006315:0.011067:0.010434:0.011682:0.010434:0.011511:0.011118:0.006636:0.006317:0.011682:0.005080:0.011118:0.006320:0.011682:0.006636:0.006636:0.011203:0.011067:0.003421:0.011682:0.005798:0.011118:0.011716:0.006329:0.014214:0.003421:0.005798:0.010434:0.006329:0.005078:0.011118:0.005679
sponse to treatment with carboplatin, pa-:@0.571279:0.235400:0.915152:0.235400:0.915152:0.221395:0.571279:0.221395:0.006636:0.011665:0.011203:0.010434:0.006636:0.011118:0.004302:0.005798:0.011203:0.004302:0.005798:0.005075:0.011118:0.011682:0.005798:0.016044:0.011118:0.010434:0.005798:0.004293:0.014214:0.003421:0.005798:0.010434:0.004300:0.011067:0.011682:0.005148:0.011665:0.011203:0.011665:0.003421:0.011682:0.005798:0.003421:0.010434:0.004738:0.004298:0.011665:0.011682:0.005679
clitaxel, and sorafenib in melanoma. :@0.571279:0.249688:0.875626:0.249688:0.875626:0.235683:0.571279:0.235683:0.011067:0.003421:0.003421:0.005798:0.011682:0.008210:0.011118:0.003421:0.004738:0.004002:0.011682:0.010434:0.011716:0.004002:0.006636:0.011203:0.005148:0.011682:0.005371:0.011118:0.010434:0.003421:0.011665:0.003994:0.003421:0.010434:0.004002:0.016044:0.011118:0.003421:0.011682:0.010434:0.011203:0.016044:0.011682:0.004738:0.004738
Clini-:@0.874865:0.249688:0.915145:0.249688:0.915145:0.235683:0.874865:0.235683:0.013906:0.003421:0.003421:0.010434:0.003421:0.005679
cal Cancer Research:@0.571279:0.263975:0.747865:0.263975:0.747865:0.249970:0.571279:0.249970:0.011067:0.011682:0.003421:0.004738:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738:0.010382:0.011118:0.006636:0.011118:0.011682:0.005148:0.011067:0.010434
. 2016;22(2):374-382.:@0.747848:0.263975:0.913024:0.263975:0.913024:0.249970:0.747848:0.249970:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.006312:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
111.    Seddon B, Strauss SJ, Whelan J, :@0.524242:0.278263:0.824338:0.278263:0.824338:0.264258:0.524242:0.264258:0.009479:0.009479:0.009479:0.004734:0.004731:0.004738:0.004396:0.000000:0.008347:0.010947:0.011545:0.011545:0.011032:0.010263:0.004139:0.009647:0.004567:0.004139:0.008347:0.005627:0.004977:0.011511:0.010228:0.006465:0.006465:0.004139:0.008347:0.008073:0.004567:0.004139:0.016249:0.010263:0.010947:0.003250:0.011511:0.010263:0.004139:0.008073:0.004567:0.250569
et al:@0.823740:0.278263:0.859385:0.278263:0.859385:0.264258:0.823740:0.264258:0.010947:0.005627:0.004139:0.011511:0.003421
. Gem-:@0.859214:0.278263:0.915162:0.278263:0.915162:0.264258:0.859214:0.264258:0.004567:0.004139:0.014744:0.010947:0.015873:0.005679
citabine and docetaxel versus doxorubicin :@0.571279:0.292550:0.919914:0.292550:0.919914:0.278545:0.571279:0.278545:0.010895:0.003250:0.005627:0.011511:0.011494:0.003250:0.010263:0.010947:0.003746:0.011511:0.010263:0.011545:0.003746:0.011545:0.011032:0.010895:0.010947:0.005627:0.011511:0.008039:0.010947:0.003250:0.003746:0.009305:0.010947:0.004977:0.006465:0.010228:0.006465:0.003746:0.011545:0.011032:0.008039:0.011032:0.004977:0.010228:0.011494:0.003250:0.010895:0.003250:0.010430:0.004738
as first-line treatment in previously untreat-:@0.571279:0.306838:0.915156:0.306838:0.915156:0.292833:0.571279:0.292833:0.011511:0.006465:0.005590:0.004079:0.004079:0.004977:0.006465:0.005627:0.005508:0.003250:0.003250:0.010263:0.010947:0.005588:0.005627:0.004907:0.010947:0.011511:0.005627:0.015873:0.010947:0.010263:0.005627:0.005590:0.003250:0.010263:0.005590:0.011494:0.004907:0.010947:0.009305:0.003250:0.011032:0.010228:0.006465:0.003250:0.008997:0.005590:0.010228:0.010263:0.005627:0.004907:0.010947:0.011511:0.005627:0.005679
ed advanced unresectable or metastatic :@0.571279:0.321125:0.919880:0.321125:0.919880:0.307120:0.571279:0.307120:0.010947:0.011545:0.005713:0.011511:0.011545:0.009305:0.011511:0.010263:0.010895:0.010947:0.011545:0.005713:0.010228:0.010263:0.004906:0.010947:0.006465:0.010947:0.010895:0.005627:0.011511:0.011494:0.003250:0.010947:0.005713:0.011032:0.004977:0.005713:0.015873:0.010947:0.005627:0.011511:0.006465:0.005627:0.011511:0.005627:0.003250:0.011067:0.004738
soft-tissue sarcomas (GeDDiS): a ran-:@0.571279:0.335413:0.915161:0.335413:0.915161:0.321408:0.571279:0.321408:0.006465:0.011032:0.005200:0.005627:0.005508:0.005627:0.003250:0.006465:0.006465:0.010228:0.010947:0.016318:0.006465:0.011511:0.004856:0.010895:0.011032:0.015873:0.011511:0.006465:0.016318:0.006140:0.014744:0.010947:0.012555:0.012555:0.003250:0.008347:0.006140:0.004567:0.016318:0.011511:0.016318:0.004977:0.011511:0.010263:0.005679
domised controlled phase 3 trial. :@0.571279:0.349700:0.845101:0.349700:0.845101:0.335695:0.571279:0.335695:0.011545:0.011032:0.015873:0.003250:0.006465:0.010947:0.011545:0.005627:0.010895:0.011032:0.010263:0.005627:0.004907:0.011032:0.003250:0.003250:0.010947:0.011545:0.005627:0.011494:0.010263:0.011511:0.006465:0.010947:0.005627:0.009305:0.005627:0.005627:0.004977:0.003250:0.011511:0.003250:0.004567:0.004738
The Lan-:@0.845991:0.349700:0.915126:0.349700:0.915126:0.335695:0.845991:0.335695:0.007115:0.010263:0.010947:0.005627:0.007731:0.011511:0.010263:0.005679
cet Oncology:@0.571279:0.363988:0.684989:0.363988:0.684989:0.349983:0.571279:0.349983:0.010895:0.010947:0.005627:0.004567:0.014693:0.010263:0.010895:0.011032:0.003250:0.011032:0.011340:0.009168
. 2017;18(10):1397-1af410.:@0.684818:0.363988:0.891199:0.363988:0.891199:0.349983:0.684818:0.349983:0.004567:0.004567:0.009305:0.009305:0.009305:0.009305:0.004567:0.009305:0.009305:0.006140:0.009305:0.009305:0.006140:0.004567:0.009305:0.009305:0.009305:0.009305:0.005508:0.009305:0.011511:0.005200:0.009305:0.009305:0.009305:0.004738
112.     Kobayakawa M, Kojima Y. Tegafur/gimer-:@0.524242:0.378275:0.915145:0.378275:0.915145:0.364270:0.524242:0.364270:0.009476:0.009476:0.009476:0.004738:0.004738:0.004738:0.004396:0.004738:-0.004738:0.010109:0.011203:0.011665:0.011682:0.009168:0.011682:0.008586:0.011682:0.014214:0.011682:0.005012:0.015719:0.004738:0.004996:0.010109:0.011203:0.003472:0.003421:0.016044:0.011682:0.005001:0.009011:0.004738:0.004998:0.006448:0.011118:0.011511:0.011682:0.005371:0.010399:0.005148:0.007475:0.011511:0.003421:0.016044:0.011118:0.005123:0.015231
acil/oteracil (S-1) approved for the treat-:@0.571279:0.392563:0.915156:0.392563:0.915156:0.378558:0.571279:0.378558:0.011682:0.011067:0.003421:0.003421:0.007475:0.011203:0.005798:0.011118:0.005148:0.011682:0.011067:0.003421:0.003421:0.005969:0.006312:0.008518:0.005679:0.009476:0.006312:0.005969:0.011682:0.011665:0.011665:0.005085:0.011203:0.009476:0.011118:0.011716:0.005969:0.005371:0.011203:0.005148:0.005956:0.005798:0.010434:0.011118:0.005957:0.005798:0.005077:0.011118:0.011682:0.005798:0.005679
ment  of advanced gastric  cancer  in :@0.571279:0.406850:0.919897:0.406850:0.919897:0.392845:0.571279:0.392845:0.016044:0.011118:0.010434:0.005798:0.004738:0.008333:0.011203:0.005371:0.013085:0.011682:0.011716:0.009476:0.011682:0.010434:0.011067:0.011118:0.011716:0.013085:0.011511:0.011682:0.006636:0.005798:0.005148:0.003421:0.011067:0.004738:0.008338:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738:0.008332:0.003421:0.010434:0.004738
adults when  given in combination with :@0.571279:0.421138:0.919892:0.421138:0.919892:0.407133:0.571279:0.407133:0.011682:0.011716:0.010399:0.003421:0.005798:0.006636:0.009596:0.014214:0.010434:0.011118:0.010434:0.004738:0.004849:0.011511:0.003421:0.009476:0.011118:0.010434:0.009596:0.003421:0.010434:0.009596:0.011067:0.011203:0.016044:0.011665:0.003421:0.010434:0.011682:0.005798:0.003421:0.011203:0.010434:0.009596:0.014214:0.003421:0.005798:0.010434:0.004738
cisplatin: a review comparing it with other :@0.571279:0.435425:0.919916:0.435425:0.919916:0.421420:0.571279:0.421420:0.011067:0.003421:0.006636:0.011665:0.003421:0.011682:0.005798:0.003421:0.010434:0.004738:0.004430:0.011682:0.004430:0.005077:0.011118:0.009476:0.003421:0.011118:0.014214:0.004430:0.011067:0.011203:0.016044:0.011665:0.011682:0.005148:0.003421:0.010434:0.011511:0.004415:0.003421:0.005798:0.004421:0.014214:0.003421:0.005798:0.010434:0.004421:0.011203:0.005798:0.010434:0.011118:0.005148:0.004738
fluoropyrimidine-based  therapies. :@0.571279:0.449713:0.860172:0.449713:0.860172:0.435708:0.571279:0.435708:0.004148:0.004148:0.010399:0.011203:0.005070:0.011203:0.011665:0.009168:0.005148:0.003421:0.016044:0.003421:0.011716:0.003421:0.010434:0.011118:0.005679:0.011665:0.011682:0.006636:0.011118:0.011716:0.004738:0.007432:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.003421:0.011118:0.006636:0.004740:-0.034646
Onco :@0.867595:0.449713:0.919900:0.449713:0.919900:0.435708:0.867595:0.435708:0.014864:0.010434:0.011067:0.011203:0.004738
Targets and Therapy:@0.571279:0.464000:0.740270:0.464000:0.740270:0.449995:0.571279:0.449995:0.007286:0.011682:0.005148:0.011511:0.011118:0.005798:0.006636:0.004738:0.011682:0.010434:0.011716:0.004738:0.007286:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168
. 2011;4:193-201.:@0.740253:0.464000:0.873855:0.464000:0.873855:0.449995:0.740253:0.449995:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
113.    Fukushima M. S-1 review from preclinical :@0.524242:0.478288:0.919881:0.478288:0.919881:0.464283:0.524242:0.464283:0.009476:0.009476:0.009476:0.004738:0.004738:0.004738:0.004396:0.000000:0.008296:0.010399:0.008586:0.010399:0.006636:0.010434:0.003421:0.016044:0.011682:0.007184:0.015719:0.004738:0.007184:0.008518:0.005679:0.009476:0.007184:0.005080:0.011118:0.009476:0.003421:0.011118:0.014214:0.007184:0.005371:0.005078:0.011203:0.016044:0.007184:0.011665:0.005080:0.011118:0.011067:0.003421:0.003421:0.010434:0.003421:0.011067:0.011682:0.003421:-0.135919
pharmacology. :@0.571279:0.492575:0.705458:0.492575:0.705458:0.478570:0.571279:0.478570:0.011665:0.010434:0.011682:0.005622:0.016044:0.011682:0.011067:0.011203:0.003421:0.011203:0.011511:0.009168:0.004738:0.004738
Gastric Cancer:@0.709397:0.492575:0.840108:0.492575:0.840108:0.478570:0.709397:0.478570:0.014915:0.011682:0.006636:0.005798:0.005148:0.003421:0.011067:0.008689:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148
. 2009;12 :@0.840108:0.492575:0.919883:0.492575:0.919883:0.478570:0.840108:0.478570:0.004738:0.008689:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009493:0.004738
(1):3-9.:@0.571279:0.506863:0.627484:0.506863:0.627484:0.492858:0.571279:0.492858:0.006312:0.009476:0.006312:0.004738:0.009476:0.005679:0.009476:0.004738
114.    Taplin ME, Regan MM, Ko YJ, :@0.524242:0.521150:0.816357:0.521150:0.816357:0.507145:0.524242:0.507145:0.009476:0.009476:0.009476:0.004738:0.004738:0.004738:0.004396:0.000000:0.006397:0.011682:0.011665:0.003421:0.003421:0.010434:0.005605:0.015719:0.009168:0.004738:0.005595:0.010382:0.011118:0.011511:0.011682:0.010434:0.005591:0.015719:0.015719:0.004738:0.005591:0.010109:0.011203:0.005590:0.010126:0.008244:0.004738:-0.094740
et al:@0.817206:0.521150:0.854818:0.521150:0.854818:0.507145:0.817206:0.507145:0.011118:0.005798:0.005593:0.011682:0.003421
. Phase :@0.854818:0.521150:0.919883:0.521150:0.919883:0.507145:0.854818:0.507145:0.004738:0.005593:0.010126:0.010434:0.011682:0.006636:0.011118:0.004738
II study of androgen  synthesis inhibition :@0.571279:0.535438:0.919890:0.535438:0.919890:0.521433:0.571279:0.521433:0.003866:0.003866:0.009749:0.006636:0.005798:0.010399:0.011716:0.009168:0.009749:0.011203:0.005371:0.009749:0.011682:0.010434:0.011716:0.005078:0.011203:0.011511:0.011118:0.010434:0.004738:0.005003:0.006636:0.009168:0.010434:0.005798:0.010434:0.011118:0.006636:0.003421:0.006636:0.009749:0.003421:0.010434:0.010434:0.003421:0.011665:0.003421:0.005798:0.003421:0.011203:0.010434:0.004738
with ketoconazole,  hydrocortisone,  and :@0.571279:0.549725:0.919885:0.549725:0.919885:0.535720:0.571279:0.535720:0.014214:0.003421:0.005798:0.010434:0.009664:0.008586:0.011118:0.005798:0.011203:0.011067:0.011203:0.010434:0.011682:0.007269:0.011203:0.003421:0.011118:0.004738:0.004738:0.004909:0.010434:0.009168:0.011716:0.005078:0.011203:0.011067:0.011203:0.005148:0.005798:0.003421:0.006636:0.011203:0.010434:0.011118:0.004738:0.004738:0.004912:0.011682:0.010434:0.011716:0.004738
dutasteride  in  asymptomatic castration-:@0.571279:0.564013:0.915159:0.564013:0.915159:0.550008:0.571279:0.550008:0.011716:0.010399:0.005798:0.011682:0.006636:0.005798:0.011118:0.005148:0.003421:0.011716:0.011118:0.004738:0.004161:0.003421:0.010434:0.004738:0.004165:0.011682:0.006636:0.009168:0.016044:0.011665:0.005798:0.011203:0.016044:0.011682:0.005798:0.003421:0.011067:0.008911:0.011067:0.011682:0.006636:0.005798:0.005148:0.011682:0.005798:0.003421:0.011203:0.010434:0.005679
resistant prostate cancer. :@0.571279:0.578300:0.785686:0.578300:0.785686:0.564295:0.571279:0.564295:0.005078:0.011118:0.006636:0.003421:0.006636:0.005798:0.011682:0.010434:0.005798:0.005046:0.011665:0.005080:0.011203:0.006636:0.005798:0.011682:0.005798:0.011118:0.005046:0.011067:0.011682:0.010434:0.011067:0.011118:0.003888:0.004738:0.004738
Clinical Cancer :@0.785994:0.578300:0.919916:0.578300:0.919916:0.564295:0.785994:0.564295:0.013906:0.003421:0.003421:0.010434:0.003421:0.011067:0.011682:0.003433:0.005046:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738
Research.:@0.571279:0.592588:0.653602:0.592588:0.653602:0.578583:0.571279:0.578583:0.010382:0.011118:0.006636:0.011118:0.011682:0.005148:0.011067:0.010434:0.004738
 2009;15(22):7099-105.:@0.653585:0.592588:0.832976:0.592588:0.832976:0.578583:0.653585:0.578583:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.006312:0.009476:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
115.    Harris KA, Weinberg V, Bok RA, :@0.524242:0.606875:0.830975:0.606875:0.830975:0.592870:0.524242:0.592870:0.009476:0.009476:0.009476:0.004738:0.004738:0.004738:0.004396:0.000000:0.011682:0.011682:0.005148:0.005148:0.003421:0.006636:0.006277:0.010109:0.012657:0.004738:0.006260:0.015618:0.011118:0.003421:0.010434:0.011665:0.011118:0.005160:0.011511:0.006277:0.010198:0.004738:0.006277:0.009818:0.011203:0.008586:0.006277:0.010382:0.012657:0.004738:-0.234048
et al:@0.832514:0.606875:0.870811:0.606875:0.870811:0.592870:0.832514:0.592870:0.011118:0.005798:0.006277:0.011682:0.003421
. Low :@0.870811:0.606875:0.919883:0.606875:0.919883:0.592870:0.870811:0.592870:0.004738:0.006277:0.007902:0.011203:0.014214:0.004738
dose ketoconazole  with replacement :@0.571279:0.621163:0.919887:0.621163:0.919887:0.607158:0.571279:0.607158:0.011716:0.011203:0.006636:0.011118:0.015565:0.008586:0.011118:0.005798:0.011203:0.011067:0.011203:0.010434:0.011682:0.007269:0.011203:0.003421:0.011118:0.004738:0.010815:0.014214:0.003421:0.005798:0.010434:0.015565:0.005078:0.011118:0.011665:0.003421:0.011682:0.011067:0.011118:0.016044:0.011118:0.010434:0.005798:0.004738
doses of hydrocortisone  in patients with :@0.571279:0.635450:0.919871:0.635450:0.919871:0.621445:0.571279:0.621445:0.011716:0.011203:0.006636:0.011118:0.006636:0.008415:0.011203:0.005371:0.008415:0.010434:0.009168:0.011716:0.005078:0.011203:0.011067:0.011203:0.005148:0.005798:0.003421:0.006636:0.011203:0.010434:0.011118:0.004738:0.003667:0.003421:0.010434:0.008415:0.011665:0.011682:0.005798:0.003421:0.011118:0.010434:0.005798:0.006636:0.008415:0.014214:0.003421:0.005798:0.010434:0.004738
progressive androgen independent pros-:@0.571279:0.649738:0.915156:0.649738:0.915156:0.635733:0.571279:0.635733:0.011665:0.005080:0.011203:0.011511:0.005071:0.011118:0.006636:0.006636:0.003421:0.009476:0.011118:0.006187:0.011682:0.010434:0.011716:0.005078:0.011203:0.011511:0.011118:0.010434:0.006166:0.003421:0.010434:0.011716:0.011118:0.011665:0.011118:0.010434:0.011716:0.011118:0.010434:0.005798:0.006175:0.011665:0.005080:0.011203:0.006636:0.005679
tate  cancer. :@0.571279:0.664025:0.688798:0.664025:0.688798:0.650020:0.571279:0.650020:0.005798:0.011682:0.005798:0.011118:0.004738:0.009654:0.011067:0.011682:0.010434:0.011067:0.011118:0.003888:0.004738:0.004738
The Journal  of  Urology:@0.698450:0.664025:0.910436:0.664025:0.910436:0.650020:0.698450:0.650020:0.007286:0.010434:0.011118:0.014402:0.008244:0.011203:0.010399:0.005148:0.010434:0.011682:0.003421:0.004738:0.009652:0.011203:0.005371:0.004738:0.009654:0.011203:0.005148:0.011203:0.003421:0.011203:0.011511:0.009168
. :@0.910407:0.664025:0.919883:0.664025:0.919883:0.650020:0.910407:0.650020:0.004738:0.004738
2002;168(2):542-545.:@0.571279:0.678313:0.736456:0.678313:0.736456:0.664308:0.571279:0.664308:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.006312:0.009476:0.006312:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
116.    https://www.pharma.us.novartis.com/:@0.524242:0.692600:0.915145:0.692600:0.915145:0.678595:0.524242:0.678595:0.009476:0.009476:0.009476:0.004738:0.004738:0.004738:0.004396:0.000000:0.011272:0.006636:0.006636:0.012503:0.007475:0.005576:0.008313:0.008313:0.015052:0.015052:0.015052:0.005576:0.012503:0.011272:0.012520:0.006465:0.016882:0.012520:0.005576:0.011238:0.007475:0.005576:0.011272:0.012041:0.010314:0.012520:0.005987:0.006636:0.004259:0.007475:0.005576:0.011905:0.012041:0.016882:-0.440173
sites/www.pharma.us.novartis.com/files/:@0.571279:0.706888:0.915253:0.706888:0.915253:0.692883:0.571279:0.692883:0.006927:0.003712:0.006081:0.011398:0.006927:0.007757:0.014504:0.014504:0.014504:0.005018:0.011956:0.010712:0.011973:0.005903:0.016335:0.011973:0.005018:0.010680:0.006927:0.005018:0.010714:0.011482:0.009767:0.011973:0.005427:0.006079:0.003712:0.006927:0.005018:0.011349:0.011482:0.016326:0.007765:0.004310:0.004298:0.003712:0.011400:0.006927:0.007475
votrient.pdf :@0.571279:0.721175:0.671887:0.721175:0.671887:0.707170:0.571279:0.707170:0.009476:0.011203:0.005798:0.005148:0.003421:0.011118:0.010434:0.005798:0.004738:0.011665:0.011716:0.005354:0.004738
117.     Serrone L, Zeuli M, Sega FM, :@0.524242:0.735757:0.808183:0.735757:0.808183:0.721752:0.524242:0.721752:0.009476:0.009476:0.009476:0.004738:0.004738:0.004738:0.004396:0.004738:-0.004738:0.008518:0.011118:0.005148:0.005080:0.011203:0.010434:0.011118:0.005653:0.007902:0.004738:0.005662:0.008210:0.011118:0.010399:0.003421:0.003421:0.005662:0.015719:0.004738:0.005662:0.008518:0.011118:0.011511:0.011682:0.005662:0.008296:0.015719:0.004738:-0.398721
et al:@0.809107:0.735757:0.846788:0.735757:0.846788:0.721752:0.809107:0.721752:0.011118:0.005798:0.005662:0.011682:0.003421
. Dacar-:@0.846788:0.735757:0.915171:0.735757:0.915171:0.721752:0.846788:0.721752:0.004738:0.005662:0.012726:0.011682:0.011067:0.011682:0.005148:0.005679
bazine-based chemotherapy  for  meta-:@0.571279:0.750044:0.915150:0.750044:0.915150:0.736039:0.571279:0.736039:0.011665:0.011682:0.007269:0.003421:0.010434:0.011118:0.005679:0.011665:0.011682:0.006636:0.011118:0.011716:0.010964:0.011067:0.010434:0.011118:0.016044:0.011203:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.004738:0.006211:0.005371:0.011203:0.005148:0.004738:0.006212:0.016044:0.011118:0.005798:0.011682:0.005679
static melanoma:  thirty-year  experience :@0.571279:0.764332:0.919904:0.764332:0.919904:0.750327:0.571279:0.750327:0.006636:0.005798:0.011682:0.005798:0.003421:0.011067:0.008723:0.016044:0.011118:0.003421:0.011682:0.010434:0.011203:0.016044:0.011682:0.004738:0.004738:0.003972:0.005798:0.010434:0.003421:0.005148:0.005798:0.009168:0.005679:0.009168:0.011118:0.011682:0.005148:0.004738:0.003968:0.011118:0.008210:0.011665:0.011118:0.005148:0.003421:0.011118:0.010434:0.011067:0.011118:0.004738
overview. :@0.571279:0.778619:0.655929:0.778619:0.655929:0.764614:0.571279:0.764614:0.011203:0.009476:0.011118:0.005148:0.009476:0.003421:0.011118:0.014214:0.004738:0.004738
Journal of  Experimental and :@0.662634:0.778619:0.919893:0.778619:0.919893:0.764614:0.662634:0.764614:0.008244:0.011203:0.010399:0.005148:0.010434:0.011672:0.003421:0.011460:0.011203:0.005371:0.004738:0.006708:0.009168:0.008210:0.011665:0.011118:0.005148:0.003421:0.016044:0.011118:0.010434:0.005798:0.011682:0.003421:0.011460:0.011682:0.010434:0.011716:0.004738
Clinical Cancer  Research.:@0.571279:0.792907:0.810381:0.792907:0.810381:0.778902:0.571279:0.778902:0.013906:0.003421:0.003421:0.010434:0.003421:0.011067:0.011682:0.003421:0.016335:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738:0.011580:0.010382:0.011118:0.006636:0.011118:0.011682:0.005148:0.011067:0.010434:0.004738
  2000;19(1): :@0.810381:0.792907:0.919873:0.792907:0.919873:0.778902:0.810381:0.778902:0.004738:0.011586:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.006312:0.009476:0.006312:0.004738:0.004738
21-34.:@0.571279:0.807194:0.619599:0.807194:0.619599:0.793189:0.571279:0.793189:0.009476:0.009476:0.005679:0.009476:0.009476:0.004738
118.     Rueda Domínguez A, Márquez A, Gumá :@0.524242:0.821482:0.919900:0.821482:0.919900:0.807477:0.524242:0.807477:0.009476:0.009476:0.009476:0.004738:0.004738:0.004738:0.004396:0.004738:-0.004738:0.010382:0.010399:0.011118:0.011716:0.011682:0.006756:0.012726:0.011203:0.016044:0.003421:0.010434:0.011511:0.010399:0.011118:0.007269:0.006739:0.012657:0.004738:0.006756:0.015719:0.011682:0.005012:0.011665:0.010399:0.011118:0.007269:0.006756:0.012657:0.004738:0.006756:0.014915:0.010399:0.016044:0.011682:0.004738
J, :@0.571279:0.835769:0.588999:0.835769:0.588999:0.821764:0.571279:0.821764:0.008244:0.004738:0.004738
et al:@0.589786:0.835769:0.627330:0.835769:0.627330:0.821764:0.589786:0.821764:0.011118:0.005798:0.005525:0.011682:0.003421
. Treatment of stage I and II Hodg-:@0.627330:0.835769:0.915126:0.835769:0.915126:0.821764:0.627330:0.821764:0.004738:0.005525:0.006773:0.005078:0.011118:0.011682:0.005798:0.016044:0.011118:0.010434:0.005798:0.005525:0.011203:0.005371:0.005525:0.006636:0.005798:0.011682:0.011511:0.011118:0.005525:0.003866:0.005525:0.011682:0.010434:0.011716:0.005525:0.003866:0.003866:0.005525:0.011682:0.011203:0.011716:0.011511:0.005679
kin’s lymphoma with ABVD chemothera-:@0.571279:0.850057:0.915145:0.850057:0.915145:0.836052:0.571279:0.836052:0.008586:0.003421:0.010434:0.006004:0.006636:0.007081:0.003421:0.009168:0.016044:0.011665:0.010434:0.011203:0.016044:0.011682:0.007081:0.014214:0.003421:0.005798:0.010434:0.007081:0.012657:0.009818:0.012007:0.012726:0.007081:0.011067:0.010434:0.011118:0.016044:0.011203:0.005798:0.010434:0.011118:0.005148:0.011682:0.005679
py: results after 7 years of a prospective :@0.571279:0.864344:0.919900:0.864344:0.919900:0.850339:0.571279:0.850339:0.011665:0.009168:0.004738:0.007201:0.005078:0.011118:0.006636:0.010399:0.003421:0.005798:0.006636:0.007201:0.011682:0.005371:0.005798:0.011118:0.005148:0.007187:0.009476:0.007192:0.009168:0.011118:0.011682:0.005148:0.006636:0.007201:0.011203:0.005371:0.007191:0.011682:0.007201:0.011665:0.005080:0.011203:0.006636:0.011665:0.011118:0.011067:0.005798:0.003421:0.009476:0.011118:0.004738
study. :@0.571279:0.878632:0.624474:0.878632:0.624474:0.864627:0.571279:0.864627:0.006636:0.005798:0.010399:0.011716:0.009168:0.004738:0.004738
Annals of Oncology:@0.629246:0.878632:0.802975:0.878632:0.802975:0.864627:0.629246:0.864627:0.012657:0.010434:0.010434:0.011682:0.003421:0.006636:0.009510:0.011203:0.005371:0.009510:0.014864:0.010434:0.011067:0.011203:0.003421:0.011203:0.011511:0.009168
. 2004;15(12): :@0.802975:0.878632:0.919876:0.878632:0.919876:0.864627:0.802975:0.864627:0.004738:0.009510:0.009476:0.009476:0.009486:0.009476:0.004738:0.009476:0.009476:0.006312:0.009476:0.009476:0.006312:0.004738:0.004738
1798-1804.:@0.571279:0.892919:0.657502:0.892919:0.657502:0.878914:0.571279:0.878914:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.009476:0.004738
119.    http://products.sanofi.us/zaltrap/zaltrap.:@0.524242:0.907207:0.914950:0.907207:0.914950:0.893202:0.524242:0.893202:0.009476:0.009476:0.009476:0.004738:0.004738:0.004738:0.004396:0.000000:0.010656:0.006021:0.006021:0.011888:0.004960:0.007697:0.007697:0.011888:0.005302:0.011426:0.011939:0.010622:0.011289:0.006021:0.006859:0.004960:0.006859:0.011905:0.010656:0.011426:0.004276:0.004276:0.004960:0.010622:0.006869:0.007697:0.007492:0.011905:0.003643:0.006021:0.005371:0.011905:0.011888:0.007697:0.007492:0.011905:0.003643:0.006021:0.005371:0.011905:0.011888:0.004738
html :@0.571279:0.921494:0.611714:0.921494:0.611714:0.907489:0.571279:0.907489:0.010434:0.005798:0.016044:0.003421:0.004738
120.     http://pi.lilly.com/us/cyramza-pi.pdf :@0.524242:0.935782:0.873428:0.935782:0.873428:0.921777:0.524242:0.921777:0.009476:0.009476:0.009476:0.004738:0.004738:0.004738:0.004396:0.004738:-0.004738:0.010434:0.005798:0.005798:0.011665:0.004738:0.007475:0.007475:0.011665:0.003421:0.004738:0.003421:0.003421:0.003421:0.003421:0.009168:0.004738:0.011067:0.011203:0.016044:0.007475:0.010399:0.006636:0.007475:0.011067:0.009168:0.005148:0.011682:0.016044:0.007269:0.011682:0.005679:0.011665:0.003421:0.004738:0.011665:0.011716:0.005371:0.004738
DRUG-CLASS OVERVIEW:@0.084848:0.038601:0.357590:0.038601:0.357590:0.019343:0.084848:0.019343:0.017498:0.014276:0.015405:0.020508:0.007808:0.019121:0.010866:0.017404:0.011712:0.011712:0.006515:0.020438:0.016510:0.012606:0.013356:0.016510:0.005315:0.012606:0.022578